List of Zelboraf drug patents

Zelboraf is owned by Hoffmann La Roche.

Zelboraf contains Vemurafenib.

Zelboraf has a total of 6 drug patents out of which 0 drug patents have expired.

Zelboraf was authorised for market use on 17 August, 2011.

Zelboraf is available in tablet;oral dosage forms.

Zelboraf can be used as zelboraf is indicated for the treatment of patients with erdheim-chester disease with braf v600 mutation; treatment of patients with unresectable or metastatic melanoma with brafv600e mutation as detected by an fda approved test.

The generics of Zelboraf are possible to be released after 06 June, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8143271 HOFFMANN LA ROCHE NA
Jun, 2026

(3 years from now)

US7504509 HOFFMANN LA ROCHE Compounds and methods for development of Ret modulators
Oct, 2026

(3 years from now)

US7863288 HOFFMANN LA ROCHE NA
Jun, 2029

(6 years from now)

US8741920 HOFFMANN LA ROCHE Process for the manufacture of pharmaceutically active compounds
Jul, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8470818 HOFFMANN LA ROCHE NA
Aug, 2026

(3 years from now)

US9447089 HOFFMANN LA ROCHE Compositions and uses thereof
Jun, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 6, 2024

Drugs and Companies using VEMURAFENIB ingredient

Market Authorisation Date: 17 August, 2011

Treatment: Zelboraf is indicated for the treatment of patients with erdheim-chester disease with braf v600 mutation; Treatment of patients with unresectable or metastatic melanoma with brafv600e mutation as detected by an fda approved test

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic